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We reviewed and analyzed safety and efﬁcacy data after mobilization with granulocyte colony-stimulating
factor (G-CSF) according to healthy donor’s (HDs) age as follows: <50 years (HDs-1, n ¼ 161), aged 50 to
59 years (HDs-2, n ¼ 62), and 60 years or over (HDs-3, n ¼ 23). Two hundred forty-six HDs were evaluated,
and their characteristics were well balanced among age groups: most were male, siblings, and HLA matched.
According to age group, the median numbers of CD34þ cells in the peripheral blood for HDs-1, HDs-2, and
HDs-3 were, respectively, 44.5, 34.5, and 26 (HDs-1 versus HDs-2, P ¼ .002; HDs-1 versus HDs-3, P ¼ .036;
HDs-2 versus HDs-3, P ¼ n.s.) at day 4 and 65.5, 58, and 46 (HDs-1 versus HDs-2, P ¼ .039; HDs-1 versus HDs-
3, P ¼ .002; HDs-2 versus HDs-3, P ¼ n.s.) at day 5. With a median apheresis session of 1, the number of CD34þ
cells/kg recipient body weight collected was not signiﬁcantly different (6.4 in HDs-1, 6.0 in HDs-2, and 5.7 in
HDs-3, P ¼ n.s.). Short- and long-term safety did not differ among age groups. Bone pain was reported as the
most frequent short-term adverse event (76.5%). After a median follow-up of 7.8 years, the observed rate of
solid tumors, hematological malignancies, and cardiovascular and autoimmune events was similar to the
expected incidence for these diseases in Western countries. These results show that G-CSF is effective in the
mobilization of older HDs. Moreover, our data contribute to the growing body of evidence in support of the
long-term safety of G-CSF for allogeneic donor stem cell mobilization also for elderly HDs.
 2015 American Society for Blood and Marrow Transplantation. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is an established procedure for many malignancies of
the hematopoietic system [1]. Over the past 15 to 20 years,
the landscape of allografting has changed, from being rarely
performed in patients50 years to accounting for a little less
than half of the transplantations reported [1,2]. The reason
for the rise in HSCT among old adults ranges from the
introduction of lower toxicity conditioning regimens to thedgments on page 887
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c-nd/4.0/).increase in the number of “ﬁt” older patients requiring
chemotherapy [3-5].
Older patients on average have older siblings who could
be considered as donors [4]; in some cases these siblings
could be the only option for patients to undergo allo-HSCT
[2]. Very few matched unrelated donors (MUDs) are over
age 50 years, and an open question is the optimal choice
between a young MUD or an older matched sibling, if they
are both available [4]. Matched sibling donors were shown to
provide improved overall survival and reduced acute graft-
versus-host disease (GVHD) relative to MUDs [6]. Other
studies show similar outcomes after matched sibling donors
compared with MUD among older patients [7].
In healthy donors (HDs), stem cells can be collected in
2 ways: bone marrow (BM) harvest or collection fromThis is an open access article under the CC BY-NC-ND license (http://
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performed under general or regional anesthesia [9], and
stem cells are directly aspirated from both hip bones
(posterior superior iliac crests). The complications of BM
harvesting are well known and are usually mild and self-
limiting. Severe side effects, such as infections, anesthetic
complications, and bleeding, have been described but are
rare [10-12]. PBSC collection involves administering sub-
cutaneous injections of granulocyte colony-stimulating
factor (G-CSF) to the donor for approximately 4 to 5 days.
The avoidance of anesthesia, blood transfusion, and pro-
longed pain are potential beneﬁts of PBSC donation [13].
The choice of stem cell source is determined by donor
preference, recipient diagnosis, disease stage, age, intended
conditioning regimen, and other factors that may
contribute to transplant-related mortality [14].
A systematic review showed that overall survival after
allo-HSCT using PBSC was similar to using BM in adults with
hematological malignancies. The authors found moderate
evidence that PBSC transplantationwas associatedwith faster
engraftment of neutrophils and platelets, but a higher risk of
GVHD, in terms of more overall and extensive chronic GVHD
[15]. Kollman et al. [16] showed the use of younger donors
may lower the incidence of GVHD and improve survival after
BM transplantation, whereas Richa et al. [6] demonstrated
that older donor age has no detrimental effect on graft func-
tion or transplant outcome after PBSC allo-HSCT.
A donor of advance d age who meets the requirements of
the mobilization proceduremay be considered. Some studies
indicate that older age correlates with mobilizing fewer
CD34þ cells in the peripheral blood and therefore lower
CD34þ cell yields [17-20]. Comorbidities do not reduce the
capacity to mobilize CD34þ cells, and medically cleared older
sibling donors aged 50 to 70 years generally have adequate
PBSC CD34þ cells for transplantation [20,21].
Although analyses comparing BM with PBSC donation
have generally demonstrated differences in adverse event
proﬁles with similar overall effects [21], few data are avail-
able to assess the efﬁcacy and short- and long-term safety of
G-CSF mobilization in an older HD population [13,22-27].
The aim of the present single-institution study was to assess
the safety and efﬁcacy of the mobilization of PBSC in older
HDs treated with G-CSF.METHODS
From 1997 to 2013, 246 consecutive HDs were referred to our transplant
unit to undergo mobilization and apheresis of PBSC for related allo-HSCT.
For this retrospective study, donors were divided into 3 groups according
to age: HDs-1, patients <age 50 years; HDs-2, patients aged 50 to 59 years;
and HDs-3, patients aged 60. Demographic, mobilization, and apheresis
characteristics from all donors were collected.
Donor evaluation comprised the following elements: (1) detailed
medical history, (2) physical assessment with special consideration of
peripheral veins, (3) electrocardiogram at rest and echocardiography, (4)
ultrasound examination of the upper abdomenwith measurement of spleen
diameter, and (5) laboratory examinations including complete blood count
with differential, clinical chemistry, urinalysis, infectious disease markers,
ABO, rhesus (Rh) typing, and pregnancy test in women of childbearing age
(urine or serum). Thrombophilia screening comprised testing for protein C,
protein S, factor VIII, and homocysteine plasmatic levels; antithrombin III
activity; and acquired activated protein C resistance.
To collect PBSCs, donors had to meet the following criteria: (1) not on
treatment with acetylsalicylic acid or antiaggregates, anticoagulants,
angiotensin-converting enzyme inhibitors, or lithium; (2) no splenomeg-
aly; (3) negative personal history of coagulation disorders or history of
iritis, episcleritis, or active autoimmune diseases; (4) no chronic cardio-
vascular and respiratory disease; (5) not a carrier of the sickle cell trait; (6)
able to provide peripheral venous access; and (7) not currently pregnant or
breastfeeding. Written informed consent of donors was obtained after adetailed description of the potential side effects and risks of G-CSF mobi-
lization and apheresis compared with BM donation with general
anesthesia.
Mobilization and Apheresis
Donors were mobilized with G-CSF (ie, lenograstim) with subcutaneous
doses of 10 mg/kg either as a single or split dose. The day of pretreatment
evaluation and the ﬁrst day of lenograstim administration were conven-
tionally considered as day 0 and day 1, respectively. Prophylaxis with
paracetamol was administered to prevent the potential side effects of
lenograstim.
CD34þ cell measurements in peripheral blood were performed during
mobilization with the International Society of Hematotherapy and Graft
Engineering (ISHAGE) single-platform method in all groups of HDs [28,29].
CD34þ cells were monitored on day 4 and daily thereafter until the
completion of apheresis. The collection of PBSCs was performed after
lenograstimstimulationusing identical procedures in all donorsonday5. The
target PBSC dose to be collected was4 106 CD34þ cells/kg recipient body
weight,whereasaminimal cell doseof2106CD34þ cells/kgwas accepted.
Apheresis was performed daily until the target dose was reached. PBSCs
were collected 1 to 2 hours after the last dose of lenograstim. Apheresis was
carried out with continuous-ﬂow apheresis equipment (COM.TEC cell
separators, AS 104/AS 204, and COM.TEC in; Fresenius Hemo-Care GmbH,
Bad Homburg, Germany) through bilateral peripheral venous access, using
citrate-dextrose as the anticoagulant. Lenograstim was continued until the
completion of stem cell collection provided that WBC count did not exceed
60  109/L. Apheresis was not performed in donors who showed a platelet
count lower than 75  109/L.
Efﬁcacy Endpoints
The primary endpoints were to evaluate the peak CD34þ cell count in
peripheral blood at days 4 and 5 during mobilization with lenograstim and
the total number of CD34þ cells per recipient and donor body weight
collected. Secondary endpoints were percentage of donors achieving
2  106 and 4  106 CD34þ cells/kg recipient and percentage of those
achieving the same targets with a single apheresis, median number of WBCs
at days 4 and 5, and mobilization failure rate. Mobilization failure was
deﬁned as a collection of CD34þ cells <2  106/kg recipient. As an efﬁcacy
evaluation, we analyzed the success of HSC engraftment in patients and the
percentage of patient treatment-related mortality, deﬁned as any death
related to a fatal complication in the absence of the underlying disease
within 100 days of transplantation.
Safety Endpoint
Safety endpoints were deﬁned as the presence of any short-term
adverse event(s), such as any death and any adverse event(s) within
30 days of donation, and long-term adverse events, such as any secondary
malignancy, autoimmune and cardiovascular disease, and any other pa-
thology occurring at any time postdonation related to HSC collection. All
donors were asked to rate G-CSFerelated adverse events as mild (grade 1),
moderate (grade 2), or severe (grade 3). Discontinuation of a G-CSFerelated
adverse event was deﬁned as grade 4. The severity of adverse events was
recorded according to the Common Terminology Criteria of Adverse Events,
version 4.
HDs were monitored daily by clinical examination and laboratory ana-
lyses during G-CSF administration and every 3 to 4 days during follow-up
until the normalization of blood counts. Subsequently, subjects were
monitored prospectively by clinical examination and hematological pa-
rameters every 6 months during the ﬁrst year of follow-up and once a year
for at least 10 years. If donors were unable to come to the hospital, theywere
solicited yearly by mail and/or by telephone to send the most recent he-
matological analyses. All data were collected in a dedicated Excel database.
The ﬁnal grade of adverse effects was provided by the clinician.
Efﬁcacy and safety endpoints were evaluated in the entire population
and according to age group. HDs were grouped according to age as HDs-1,
patients <50 years; HDs-2, patients aged 50 to 59 years; and HDs-3, pa-
tients aged 60.
Statistical Analysis
Data were reported for the whole patient population and according to
HD age group. HDs groups (HDs-1, HDs-2, and HDs-3) were summarized by
appropriate statistics consisting of median, minimum, and maximum for
continuous variables, whereas categorical variables were reported in tables
as absolute and relative frequencies and in graphs as relative frequencies.
One-way analysis of variance was used for the analysis of continuous vari-
ables. Pearson’s chi-square test or Fisher’s exact test, if deemed more
appropriate, was used for the analysis of categorical outcomes. For recipient
patients, age, type of tumor, and gender were recorded.
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niﬁcant. Statistical calculations were carried out using SAS software (version
9.2; SAS Institute, Cary, NC).
RESULTS
Two hundred forty-six consecutive HDs were entered in
the database, among them 161 (65.5%) were<50 years (HDs-
1), 62 (25.2%) were aged 50 to 59 years (HDs-2), and 23 (9.3%)
were 60 (HDs-3). HD characteristics are listed in Table 1.
HD characteristics were well balanced among age groups,
and no statistical differences were detected among them.
Overall, the HD population median weight was 73 kg (range,
44 to 135) and median WBC, median hemoglobin, hemato-
crit, and platelet counts were 6.4  109/L (range, 4.0 to 13.8),
14.0 g/L (range, 10.0 to 17.4), 42% (range, 32.6% to 53.7%), and
230  109L (range, 118 to 430), respectively.
Efﬁcacy of Mobilization
As the primary endpoints, the median numbers of CD34þ
cells/mL in the peripheral blood according to age group were,
respectively, 44.5, 34.5, and 26 for HDs-1, HDs-2, and HDs-3
(HDs-1 versus HDs-2, P¼ .002; HDs-1 versus HDs-3, P¼ .036;
HDs-2 versus HDs-3, P ¼ n.s.) at day 4 and 65.5, 58, and 46
(HDs-1 versus HDs-2, P¼ .039; HDs-1 versus HDs-3, P¼ .002;
HDs-2 versus HDs-3, P ¼ n.s.) at day 5. The total numbers of
CD34þ cell/kg recipient and donor were 6.4 (range, 0 to 17.5),
6.0 (range, .9 to 17.1), and 5.7 (range, .8 to 12) (P ¼ n.s.) and
6.6 (range, 0 to 22.2), 6.2 (range, .7 to 17.7), and 5.4 (range, .9
to 18) in the HDs-1, HDs-2, and HDs-3 groups, respectively
(P ¼ n.s.). Apheresis session number, blood volumes pro-
cessed, and CD34þ cell yield/kg recipient and donor body
weight data across the 3 groups are summarized in Table 2.
Most of the HD mobilized stem cells, approximately 96%
(235/246) and 89% (219/246), achieved targets of 2  106
and4106 CD34þ cells/kg recipient, respectively. Figures 1
and 2 report the CD34þ target collection achieved according
to age group; no signiﬁcant differences were observed
within groups (P ¼ .093). Among those HDs achieving
2106 CD34þ cells/kg in a single leukapheresis, 91.9% (215/
234) successfully met target requirements. No differences by
age were observed in the percentage of donors achievingTable 1
HD Characteristics
Variable HDs-1
(n ¼ 161)
HDs-
(n ¼
Gender, % (n)
Male 53.5 (86) 66.1
Female 46.5 (75) 33.9
Median age, yr (range) 38 (18-49) 55
Donor relationship, % (n)
Sibling 97.5 (157) 96.8
Parent/child 2.5 (4) 3.2
HLA matching, % (N)
Matching 92.7 (149) 95.2
Mismatching .5 (1) 0
Haploidentical 6.8 (11) 4.8
Median donor weight, kg (range) 71 (44-135) 77
Median BMI (range) 24.6 (15.9-44.3) 26.3
Median WBC count,  109/L (range) 6.7 (4.0-13.8) 7.1
Median hematocrit, % (range) 41.4 (32.6-50.0) 42.6
BMI indicates body mass index.target CD34þ cells with a single apheresis. Data of HD
achievement of CD34þ cell collection target are detailed in
Figure 3.
Mobilization failure ratewas 4.3% (7/161), 1.6% (1/62), and
13% (3/23) in HDs-1, HDs-2, and HDs-3, respectively
(P ¼ .075). Two donors, both in the HDs-1 group, did not
perform the apheretic procedure: the ﬁrst had a CD34þ cell
count of 3/mL in peripheral blood at days 5 and 6, and the
second developed a serious side effects (see Short-Term
Safety, below). No donors were excluded because of a
platelet count <75  109/L.
Short-Term Safety
Adverse events occurring within 30 days after mobiliza-
tion and PBSC collection were deﬁned as short-term events
(Table 3). One grade 4 adverse event was reported in a 36-
year-old donor (brother) who developed shortness of
breath, rapid breathing, chest pain, and cough on the
morning of day 5 [30]. Chest multislice computed tomogra-
phy with radiocontrast agent showed multiple ﬁlling defects
of the subsegmental branches of the left pulmonary artery,
and electrocardiogram showed a sinus tachycardia of 120
beats per minute and right bundle branch block. Blood tests
showed a D-dimer level of 4285 ng/mL. A clinical diagnosis of
pulmonary embolism was suspected. He responded well to
treatment and improved clinically within 2 hours. He was
kept under observation, and then a BM harvest was per-
formed to ensure transplant to the brother.
The most frequently reported adverse event was bone
pain. Among the different HD age groups, splenomegaly
(P ¼ .020) and fatigue (P ¼ .033) had a higher incidence in
older patients. Spleen enlargement and fatigue resolved
within 2 weeks. Hemochrome values at day 30 were normal
in 97.9% of HDs (241/246) overall and in 97.5% of HDs-1 (157/
161), 98.4% in HDs-2 (61/62), and 100% in HDs-3 (23/23).
Long-Term Follow-Up
After a median follow up of 7.8 years, 97.5% (240/246),
96.7% (238/246), and 76.8% (189/246) of HDs were free from
secondary tumors, autoimmune disease, and cardiovascular2
62)
HDs-3
(n ¼ 23)
P
(41) 47.8 (11) n.s.
(21) 52.2 (12)
(50-59) 62 (60-70) HDs-1 vs. HDs-2 < .001
HDs-1 vs. HDs-3 < .001
HDs-2 vs. HDs-3 < .001
(60) 100 (23) n.s.
(2) 0
(59) 91.3 (21) n.s.
0
(3) 8.7 (2)
(45-101) 73 (44-120) n.s.
(18.5-37.6) 27.6 (19.7-37.9) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ .010
HDs-2 vs. HDs-3 ¼ n.s.
(4.4-10.6) 6.5 (4.4-9.1) n.s.
(34.6-53.7) 41 (36.9-48.2) HDs-1 vs. HDs-2 ¼ .035
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ .088
Table 2
Efﬁcacy of HSC Mobilization According to Age Group
Variable HDs-1
(n ¼ 161)
HDs-2
(n ¼ 62)
HDs-3
(n ¼ 23)
P
WBC count day 4,  109/L 40.4 (12.4-10.2) 38.0 (22.3-70.9) 33.9 (22.1-54.0) HDs-1 vs. HD-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ .010
HDs-2 vs. HDs-3 ¼ n.s.
WBC count day 5,  109/L 42.8 (13.1-90.0) 40.8 (21.1-65.0) 36.2 (24.6-61.4) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ .09
HDs-2 vs. HDs-3 ¼ n.s.
CD34þ cell day 4, mL 44.5 (3-217) 34.5 (9-92) 26 (5-138) HDs-1 vs. HDs-2 ¼ .002
HDs-1 vs. HDs-3 ¼ .036
HDs-2 vs. HDs-3 ¼ n.s.
CD34þ cell day 5, mL 65.5 (3-299) 58 (9-234) 46 (7-738) HDs-1 vs. HDs-2 ¼ .039
HDs-1 vs. HDs-3 ¼ .002
HDs-2 vs. HDs-3 ¼ n.s.
Apheresis session 1 (0-4) 1 (1-4) 1 (1-2) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Blood volume processed on day 5, L 12.5 (.8-20.1) 12.2 (6.8-21.1) 13.0 (7.8-17) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs- 3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Blood volume processed on day 6, L 13.2 (5.6-21) 12.2 (4.9-18.1) 11.8 (5.6-17.0) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Total CD34þ cells collected 450 (0-1330) 442 (69-1096) 379 (77-960) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Total CD34þ cell yield/kg recipient body weight collected 6.4 (0-17.5) 6.0 (.9-17.1) 5.7 (.8-12) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Total CD34þ cell yield/kg donor body weight collected 6.6 (0-22.2) 6.2 (.7-17.7) 5.4 (.9-18) HDs-1 vs. HDs-2 ¼ n.s.
HDs-1 vs. HDs-3 ¼ n.s.
HDs-2 vs. HDs-3 ¼ n.s.
Values are expressed as either median or percentage with ranges in parentheses.
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cohort was 8.3 (range, .1 to 16.2), 6.6 (range, .1 to 16.9), and
6.7 (range, .1 to 15.6) years in HDs-1, HDs-2, and HDs-3,
respectively. Seven secondary malignancies were detected:
a single case of colon, testis, and thyroid cancer in the HDs-1
group; 2 lung and 1 breast cancer in the HDs-2 group; and 1
uterine cancer in the HDs-3 group. Nine autoimmune dis-
eases were detected, all in the HDs-1 group: single cases of
arthritis, psoriasis, and spondylosis and 6 cases of Hashi-
moto’s thyroiditis. Fifty-eight cardiovascular diseases were
detected during follow-up, most frequently hypertension in
33, 11, and 4 patients in the HDs-1, HDs-2, and HDs-3 groups,
respectively. Other cardiovascular diseases were single cases
of pulmonary embolism, stroke, and acute myocardial
infarction and cardiac valvulopathy in the HDs-1 group and 2
strokes, 2 acutemyocardial infarctions, and 1 aortic occlusionFigure 1. Percentage of HDs achieving >2  106 CD34þ cells/kg (P ¼ .093). Datein the HDs-2 group. In the HDs-3 group 1 case of stroke was
detected.Patient Characteristics
Patients receiving allo-HSCT were mostly male, 58.7%
(145/247), weighing amedian of 72 kg (range, 40 to 130), and
with a median age of 46 years (range, 18 to 70); 76.9% (190/
247) were diagnosed with leukemia, and most received
reduced-intensity conditioning (54.8% [135/246]). Engraft-
ment was successfully obtained in 91.0% of patients (224/
246), with a distribution according to HD age of 91.9% in HDs-
1 (148/161), 93.5% in HDs-2 (58/62), and 78.3% in HDs-3 (18/
23) (P ¼ .04). Transplant-related mortality rate was 6.9% (17/
246) with an age distribution age of 6.2% in HDs-1 (10/161),
6.5% in HDs-2 (4/62), and 13% in HDs-3 (3/23) (P ¼ .132).are presented for the entire cohort (HDs-All) and according to age group.
Figure 2. Percentage of HDs achieving >4  106 CD34þ cells/kg (P ¼ .963). Date are presented for the entire cohort (HDs-All) and according to age group.
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The incidence of hematological malignancies is increasing
in older adults, and for most the current median age of
diagnosis is in the mid-70s [4]. Allo-HSCT is a milestone
procedure used to treat and cure hematological malignancies
in young patients (usually age <65 years), but the intro-
duction of lower toxicity conditioning regimens and the
improvement of supportive care have currently enhanced
the use of transplant [31-33] in older patients. In fact, pa-
tients aged 50 to 70 years with high-risk hematological
malignancies, good performance status, and no severe
comorbidities may be considered for allo-HSCT early in the
disease course [4,5].
Allo-HSCT needs an HD, with the source of stem cells
usually found among the siblings of patients. It follows
therefore that older patients may on average have older
siblings who could be considered as donors [4]. PBSC mobi-
lization is a well-studied and safe procedure established for
young HDs. Few data are available on the safety and efﬁcacy
of mobilization of PBSCs in older HDs aged 50 and above and
for donors >60 years [4,13,34].
The safety of the donor is of the utmost concern, and in
our institution HD data have been systematically collected
and stored in a database since 1997. Because of this database
we were able to analyze the efﬁcacy and safety data of HSC
mobilization in HDs in the older age subgroup (range, 50
and 60 years) from 1997 to 2013. Nearly all HDs mobilized
HSCs, and no particular short- and long-term adverse events
were detected.
Our analysis conﬁrms the safety of lenograstim in HSC
mobilization and also in older HDs over age 60 years. TheFigure 3. Percentage of HDs achieving >2  106 CD34þ cells/kg (P ¼ .015) and >4  1
entire cohort (HDs-All) and according to age group.safety of lenograstim has also been investigated in clinical
trials [26] that deﬁned the long-term safety proﬁle of G-CSF
in nearly 4000 HDs.
Different groups have investigated the inﬂuence of
several factors on the stem cell mobilization of HDs, and
analyses revealed a better mobilization in male than in fe-
male donors [35]. Higher body weight or higher body mass
index of the donors enhanced mobilization efﬁcacy in all
studies investigating this parameter [19-21,36-38]. Data from
other researchers showed the controversial impact of donor
age on mobilization efﬁcacy [12,16-21,39-42]. This ﬁnding is
clinically relevant with regards to the increasingly older
patient populationwith sibling donors of comparable age [4].
Al-Ali et al. [40] showed that an increasing age of
matched-related siblings did not preclude successful mobi-
lization and collection of HPCs and seemed to have no
negative impact on both subsequent engraftment and the
incidence of acute as well as chronic GVHD in the recipient.
For the ﬁrst time, the authors described a higher natural
killer cell count encountered in grafts from elderly donors.
Motlló et al. [27] showed that donor age also had some
impact onmobilization results using either a 55-year or a 60-
year cut-off value, but the total number of CD34þ cells
collected was not signiﬁcantly different according to donor
age, probably because of the large-volume apheresis proce-
dure involved. Ings et al. [36] evaluated the CD34þ cells
collected after mobilization with G-CSF and analyzed the
differences in CD34þ yields according to donor age (cut-off of
55 years); higher yields were obtained in younger donors.
Rinaldi et al. [42] analyzed the peak value of PBSC CD34þ
cells in 150 donors, which resulted to be lower in donors06 CD34þ cells/kg (P ¼ .548) with a single apheresis. Date are presented for the
Table 3
Short-Term Toxicity G-CSF
Variable HDs-1
(n ¼ 161)
HDs-2
(n ¼ 62)
HDs-3
(n ¼ 23)
P
Bone pain
No 21.7 (35) 25.8 (16) 26.1 (6) n.s.
Grade 1 37.3 (60) 45.2 (28) 52.2 (12)
Grade 2 34.1 (55) 24.2 (15) 13 (3)
Grade 3 6.9 (11) 4.8 (3) 8.7 (2)
Fever
No 91.9 (148) 100 (62) 91.3 (21) n.s.
Yes 8.1 (13) 0 8.7 (2)
Headache
No 67.0 (108) 69.4 (43) 73.9 (17) n.s.
Yes 33.0 (53) 30.6 (19) 26.1 (6)
Nausea
No 85.0 (137) 90.3 (56) 91.3 (21) n.s.
Yes 15.0 (24) 9.7 (6) 8.7 (2)
Splenomegaly
No 94.4 (152) 98.4 (61) 82.6 (19) .020
Yes 5.6 (9) 1.6 (1) 17.4 (4)
Insomnia
No 80.1 (129) 77.4 (48) 69.6 (16) n.s.
Yes 19.9 (32) 22.6 (14) 30.4 (7)
Fatigue
No 73.9 (119) 72.6 (45) 50 (12) .033
Yes 26.1 (42) 27.4 (17) 50 (12)
Values are percents, with total number of cases in parentheses.
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were collected in donors <55 years old, but the absolute
number of CD34þ cells collected was not provided. A
signiﬁcantly higher number of CD34þ cells was also obtained
in young donors (38 years old) in the study by De La Rubia
et al. [37] in which the target (4  106 CD34þ cells/kg
recipient) was achieved more frequently in young donors.
The same results were described in the study by Anderlini
et al. [39] in which the cut-off age was 55 years. By contrast,
Favre et al. [12] did not show differences in CD34þ cell yield
according to donor age.
Taken as a whole, these results suggest that older donor
age correlates with reduced yields from stem cell harvests
[43]. The reason for this age effect was not elucidated
clearly and could be correlated to the fact that BM reserves
decrease with age and with normal human aging, muta-
tions that might interfere with PBSC mobilization accu-
mulation [44]. However, compared with BM source, dose
issues related to age may be less problematic from PBSC
grafts because more CD34þ cells are often obtained [45]
and cell dose can be enhanced by escalating the volume
collected and infused.
PBSCs from siblings should be the preferred source,
especially in donors aged60 years, because PBSC yields are
more predictable relative to BM [4]. Although BM and PBSC
collection procedures differ greatly, the main symptoms
experienced by BM and PBSC donors are similar [46], and
published data do not clearly indicate 1 method of collection
as “safer” than the other [21]. Moreover, late toxicities such
as thrombosis, autoimmune illness, or cancer appear to be
similar in BM and PBSC donors, suggesting G-CSF does not
increase the risk of these events [44].
The assessment of the donor before HSC collection should
be based on a good understanding of the different risks
associated with both BM and PBSC collection [47]. In this
context it is essential to clarify the eligibility criteria for
donation. We believe that performance status and comor-
bidities should be considered as factors deﬁning donor
eligibility rather than age for both procedures. Older siblingdonors require special attention because many diseases
occur with higher frequency and can increase the risk of
complication of PBSC mobilization and collection. In our
institutional experience we routinely use investigations such
as echocardiography and ultrasound examination of the
upper abdomen with special attention to hematological ab-
normalities such as macrocytic anemia or lymphocytosis,
which could represent a precursor hematological malig-
nancy. Additional investigations (eg, exercise electrocardio-
gram, echo Doppler of the supraaortic vessels) and
subspecialty consultations could be required in these donors.
Hypertension may be exacerbated by bone pain, and elec-
trolyte disturbances from diuretics may be worsened from
leukapheresis [4].
In the present study, we observed that older donor age
has no detrimental effects on mobilization with G-CSF and
PBSC collection. The CD34þ cell count in peripheral blood
before apheresis is the most robust predictor for poor PBSC
collection [48,49]. At days 4 and 5 the median number of
CD34þ cells was higher in the youngest patients; however,
older HDs, albeit more slowly, mobilized a high peak number
of CD34þ cells in peripheral blood producing a total CD34þ
cell yield/kg recipient body weight that was not statistically
different with the same number of apheresis sessions. HDs-3
seemed to have lower engraftment (78% versus >90% in the
other groups) but other factors contribute to engraftment,
and we believe this result is not critical to the overall analysis
of the study.
Moreover, in allo-HSCT the importance of cell dose on
transplantation outcomes has been demonstrated by multi-
ple studies [48,49]. Although the absolute lower threshold to
guarantee engraftment is not known, the generally accepted
minimal cell dose is 2  106 CD34þ cells/kg. Higher doses
result in faster engraftment, reduced rates of infection, and
lower nonrelapse mortality; a target CD34þ cell dose be-
tween 4 and 5  106 CD34þ cells/kg seems most reasonable
based on available data.
Bone pain was the most frequently reported short-term
adverse event as expected, and its incidence was not
different among the age groups. The only signiﬁcant differ-
ence among groups was for splenomegaly (P ¼ .020) and
fatigue (P ¼ .033); both had a higher incidence in older pa-
tients and resolved within a few weeks.
To date, few studies [25,26] have investigated the long-
term consequences in HDs mobilized with lenograstim or
whether this drug can induce or contribute to leukemo-
genesis in normal subjects. In both studies, lenograstim
was demonstrated to be safe. In the present study we
investigated safety in “older” HDs. Incidence of secondary
tumors and autoimmune and cardiovascular diseases were
equally distributed in the age groups and are similar to
those expected in the general population [50-52].
In conclusion, we believe there is relative lack of data
regardingPBSCmobilizationoutcomes inolderHDs, and in this
regard this report could be useful. However, our cohort at the
higher extreme of age (60þ) was relatively small, which could
limit the utility of these data. In our study, lenograstim was
demonstrated to be effective both in themobilization of young
and old HDs. Moreover, after a long follow-up, our data
contribute to the growing body of evidence of the long-term
safety of G-CSF for allogeneic stem cell mobilization also for
elderly HDs. In the era of older family donors with possible
comorbidities, long-term safety after donation becomes even
more important than ever before.
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